Lupin trades flat after launch of Bromfenac Ophthalmic Solution

Lupin said that it was the exclusive first-to-file for Bromfenac Ophthalmic Solution, 0.07%, and is eligible for 180-day exclusivity.

Bromfenac Ophthalmic Solution (RLD Prolensa®) had estimated annual sales of USD 182 million (Rs 1515 crore) in the U.S. (IQVIA MAT November 2023). Photo: File/Representational

Lupin Share Price: Lupin shares were trading flat on Wednesday (January 10, 2024) after the pharma company launched Bromfenac Ophthalmic Solution, 0.07%, with approval from the US FDA.

The stock was trading at Rs 1396.80 at 9:58 am on Wednesday.

Lupin said that it was the exclusive first-to-file for Bromfenac Ophthalmic Solution, 0.07%, and is eligible for 180-day exclusivity.

TRENDING NOW

"Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa® Ophthalmic Solution, 0.07%, of Bausch & Lomb Inc. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery," said the company in a statement on Wednesday.

Bromfenac Ophthalmic Solution (RLD Prolensa®) had estimated annual sales of USD 182 million (Rs 1515 crore) in the U.S. (IQVIA MAT November 2023).

TAGS: